Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Payables (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Payables for 11 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Payables rose 347.22% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, up 347.22% year-over-year, with the annual reading at $1.3 million for FY2025, 347.22% up from the prior year.
  • Payables for Q4 2025 was $1.3 million at Cartesian Therapeutics, down from $2.2 million in the prior quarter.
  • The five-year high for Payables was $3.2 million in Q4 2023, with the low at $154000.0 in Q2 2021.
  • Average Payables over 5 years is $1.1 million, with a median of $555500.0 recorded in 2021.
  • Peak annual rise in Payables hit 971.91% in 2024, while the deepest fall reached 90.86% in 2024.
  • Over 5 years, Payables stood at $224000.0 in 2021, then skyrocketed by 41.07% to $316000.0 in 2022, then surged by 896.84% to $3.2 million in 2023, then tumbled by 90.86% to $288000.0 in 2024, then surged by 347.22% to $1.3 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $1.3 million, $2.2 million, and $454000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.